Income Before Tax

Income (Loss) from Continuing Operations Before Income Taxes, Foreign

Vertex Pharmaceuticals Income (Loss) from Continuing Operations Before Income Taxes, Foreign remained flat by 0.0% to $455.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.6%, from $404.55M to $455.50M. Over 2 years (FY 2023 to FY 2025), Income (Loss) from Continuing Operations Before Income Taxes, Foreign shows an upward trend with a 18.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026

How to read this metric

Higher values indicate successful international expansion and global market demand.

Detailed definition

The pre-tax income or loss generated from operations conducted outside the company's home country. This reflects the pro...

Peer comparison

Standard geographic segment reporting for multinational corporations.

Metric ID: ms_income_before_tax_foreign

Historical Data

3 years
 FY'23FY'24FY'25
Value$1.29B$1.62B$1.82B
YoY Change+25.4%+12.6%
Range$1.29B$1.82B
CAGR+18.8%
Avg YoY Growth+19.0%
Median YoY Growth+19.0%
Current Streak2+ years growth

Income (Loss) from Continuing Operations Before Income Taxes, Foreign at Other Companies

Frequently Asked Questions

What is Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, foreign?
Vertex Pharmaceuticals (VRTX) reported income (loss) from continuing operations before income taxes, foreign of $455.50M in Q4 2025.
How has Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, foreign changed year-over-year?
Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, foreign increased by 12.6% year-over-year, from $404.55M to $455.50M.
What is the long-term trend for Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, foreign?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's income (loss) from continuing operations before income taxes, foreign has grown at a 18.8% compound annual growth rate (CAGR), from $1.29B to $1.82B.
What does income (loss) from continuing operations before income taxes, foreign mean?
Pre-tax profit earned from international operations.